|
Jun 6
|
Why Is Denali Therapeutics (DNLI) Up 15.6% Since Last Earnings Report?
|
|
Jun 6
|
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
|
|
Jun 6
|
Data needed to forge the link between AI and mRNA
|
|
Jun 5
|
Usher and Apple CEO Tim Cook had a meeting. Now the Super Bowl performer is taking his ideas to Capitol Hill
|
|
May 31
|
FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease
|
|
May 31
|
FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD
|
|
May 31
|
Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More
|
|
May 31
|
Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan
|
|
May 31
|
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
|
|
May 31
|
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
|
|
May 31
|
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
|
|
May 31
|
Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation
|
|
May 30
|
Press Release: Sanofi completes acquisition of Inhibrx, Inc.
|
|
May 29
|
Sanofi’s CEO is giving OpenAI access to its data in the hope of developing drugs more quickly
|
|
May 29
|
3 High-Yielding Dividend Stocks On Euronext Paris With Up To 4.2% Yield
|
|
May 28
|
FDA accepts Sanofi’s Sarclisa sBLA for priority review
|
|
May 27
|
Sanofi's (SNY) Sarclisa sBLA Gets FDA's Priority Review Tag
|
|
May 27
|
Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma
|
|
Jan 16
|
IGM Bio (IGMS) Stock Rallies 142% in 3 Months: Here's Why
|
|
Jan 16
|
4 Pharma Stocks to Buy, According to an Analyst. Novo Nordisk Isn’t One.
|